An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis

Trial Profile

An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs Ivacaftor (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 22 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 25 Jul 2014 Planned number of patients changed from 80 to 95 as reported by ClinicalTrials.gov record.
    • 25 Jul 2014 Planned End Date changed from 1 May 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top